| Project/Area Number |
17K15035
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Miyagi Prefectural Hospital Organization Miyagi Cancer Center |
|---|
Principal Investigator |
Yamazaki Tomoko 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 特任研究員 (20792493)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2017: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 下咽頭癌 / 頭頸部癌 / 扁平上皮癌 / CD271 |
|---|
| Outline of Final Research Achievements |
We examined the role of CD271, as we reported previously, in cancer stem cells. We identified ERK pathway as a downstream of CD271. We also establieshed anti-CD271 antibody, and confirmed that CD271-targeting therapy using anti-CD271 antibody is useful at least in mice xenograft model. We will try to identify the cancer stem cell specific pathway in CD271-positive cancer stem cells and modify the anti-CD271 antibody to improve the therapeutic effect.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は肺癌や咽頭癌といった扁平上皮癌における癌幹細胞の解明を進めたものであり、今後新たな治療標的となることが予想される。
|
